AKT1 and neoplasm: It is thus possible, that guided by molecular characterization of tumor lesions, we could use PI3K, AKT or mTOR inhibitors to disrupt AKT/mTOR signaling and inhibit S6 and PRAS40 activities as an effective approach to treat HCC.